Reported 2 days ago
Eli Lilly's stock has remained steady since mid-2024, but growth in its diabetes and obesity treatments, particularly the GLP-1 medication tirzepatide, is set to boost sales significantly. Anticipated annual sales from these treatments could exceed $60 billion by 2030, potentially doubling total revenue. Despite current valuation concerns, analysts suggest that this growth might lead to substantial returns for investors in the coming years, positioning Eli Lilly as a strong contender in the pharmaceutical market.
Source: YAHOO